/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

PHARVARIS NV Share Price Today: Live Updates & Key Insights

PHARVARIS NV share price today is $26.38, up -3.83%. The stock opened at $26.79 against the previous close of $27.43, with an intraday high of $26.83 and low of $26.26.

PHARVARIS NV Share Price Chart

style
pb-0

PHARVARIS NV

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

PHARVARIS NV Share Price Performance

$26.38 -0.0383(-3.83%) PHVS at 13 Mar 2026 02:45 PM Biotechnology
Lowest Today 26.26
Highest Today 26.83
Today’s Open 26.79
Prev. Close 27.43
52 Week High 29.80
52 Week Low 11.51
Day’s Range: Low 26.26 High 26.83
52-Week Range: Low 11.51 High 29.80
1 day return -
1 Week return +1.77
1 month return +0.03
3 month return +10.21
6 month return +11.99
1 year return +52.63
3 year return +276.14
5 year return -28.48
10 year return -

PHARVARIS NV Institutional Holdings

Fidelity Growth Compy Commingled Pl S 2.70

Fidelity Growth Company Fund 1.94

Fidelity Select Health Care 1.23

Fidelity Small Cap Growth 1.17

Fidelity Advisor Health Care I 0.77

Polar Capital Biotech S Inc 0.77

Fidelity Growth Company K6 0.57

Fidelity Series Growth Company 0.55

Fidelity Small Cap Growth K6 0.51

Wellington Global Hlthcr Eq USD G Ac 0.35

iShares Biotechnology ETF 0.30

Fidelity Select Biotechnology 0.23

Vanguard International Explorer Inv 0.20

Wellington Intl Small Cap Research 0.20

Fidelity VIP Health Care Initial 0.19

iShares Core MSCI EAFE ETF 0.17

iShares MSCI EAFE Small-Cap ETF 0.13

Xtrackers MSCI Eur Small Cap ETF 1C 0.09

State St Gbl Sm Cp Eq ex-US Indx NL Cl A 0.07

iShares Nasdaq US Biotech ETF USD Acc 0.07

PHARVARIS NV Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 1

Strong Sell: 0

PHARVARIS NV Fundamentals

Market Cap 1781.84 M

PB Ratio 4.9128

PE Ratio 0.0

Enterprise Value 1400.02 M

Total Assets 291.37 M

Volume 125011

PHARVARIS NV Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-107324073 -107.3M, FY22:-76332557 -76.3M, FY21:-42730779 -42.7M, FY20:-25985704 -26.0M, FY19:-8044043 -8.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:-97024 -0.1M, Q3/2024:null 0.0M, Q2/2024:-69024 -0.1M

Quarterly Net worth Q3/2025:-37137035 -37.1M, Q2/2025:-45480686 -45.5M, Q1/2025:-46340823 -46.3M, Q3/2024:-41710758 -41.7M, Q2/2024:-29731073 -29.7M

About PHARVARIS NV & investment objective

Company Information Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Organisation Biotechnology

Employees 118

Industry Biotechnology

CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow